Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation

Journal of Diabetes and its Complications

Volumn 24, Issue 3, 2010, Pages 209-213

  White, Perrin C ^a   Chamberlain Shea, Heidi ^b   de la Morena, Maria Teresa ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Endocrine Associates of Dallas   (United States)

Author keywords

ATP; Bioluminescence; Dipeptidyl peptidase IV; Immune suppression

Indexed keywords

ADENOSINE TRIPHOSPHATE; HEMOGLOBIN A1C; PHYTOHEMAGGLUTININ; SITAGLIPTIN;

ADULT; AGED; ARTICLE; BIOLUMINESCENCE; BODY MASS; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ETHNIC DIFFERENCE; FEMALE; HUMAN; IMMUNE FUNCTION TEST; IN VITRO STUDY; MALE; MITOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX DIFFERENCE; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; BLOOD GLUCOSE; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PYRAZINES; TRIAZOLES;

EID: 77953135603     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2009.09.001     Document Type: Article

References (18)

1. Amori R.E., Lau J., and Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 298 (2007) 194-206
2. Augustine N.H., Pasi B.M., and Hill H.R. Comparison of ATP production in whole blood and lymphocyte proliferation in response to phytohemagglutinin. Journal of Clinical Laboratory Analysis 21 (2007) 265-270
3. Aytac U., and Dang N.H. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Current Drug Targets. Immune, Endocrine and Metabolic Disorders 4 (2004) 11-18
4. Basinski T.M., Holzmann D., Eiwegger T., Zimmermann M., Klunker S., Meyer N., Schmid-Grendelmeier P., Jutel M., and Akdis C.A. Dual nature of T cell-epithelium interaction in chronic rhinosinusitis. The Journal of Allergy and Clinical Immunology 124 (2009) 74-80
5. Buttgereit F., Burmester G.R., and Brand M.D. Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunology Today 21 (2000) 192-199
6. Deacon C.F., Johnsen A.H., and Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. The Journal of Clinical Endocrinology and Metabolism 80 (1995) 952-957
7. Kameoka J., Sato T., Torimoto Y., Sugita K., Soiffer R.J., Schlossman S.F., Ritz J., and Morimoto C. Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. Blood 85 (1995) 1132-1137
8. Kato A., and Schleimer R.P. Beyond inflammation: Airway epithelial cells are at the interface of innate and adaptive immunity. Current Opinion Immunology 19 (2007) 711-720
9. Kowalski R., Post D., Schneider M.C., Britz J., Thomas J., Deierhoi M., Lobashevsky A., Redfield R., Schweitzer E., et al. Immune cell function testing: An adjunct to therapeutic drug monitoring in transplant patient management. Clinical Transplantation 17 (2003) 77-88
10. Kowalski R.J., Post D.R., Mannon R.B., Sebastian A., Wright H.I., Sigle G., Burdick J., Elmagd K.A., Zeevi A., et al. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 82 (2006) 663-668
11. Kowalski R.J., Zeevi A., Mannon R.B., Britz J.A., and Carruth L.M. Immunodiagnostics: Evaluation of functional T-cell immunocompetence in whole blood independent of circulating cell numbers. J Immunotoxicol 4 (2007) 225-232
12. Marguet D., Baggio L., Kobayashi T., Bernard A.M., Pierres M., Nielsen P.F., Ribel U., Watanabe T., Drucker D.J., and Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proceeding of the National Academy of Sciences of the United State of America 97 (2000) 6874-6879
13. Nathan D.M. Finding new treatments for diabetes-how many, how fast...how good?. New England Journal of Medicine 356 (2007) 437-440
14. Preller V., Gerber A., Togni M., Wrenger S., Schraven B., Rocken C., Marguet D., Ansorge S., Brocke S., and Reinhold D. CD26/DP IV in T cell activation and autoimmunity. Advances in Experimental Medicine and Biology 575 (2006) 187-193
15. Reinhold D., Bank U., Buhling F., Lendeckel U., Faust J., Neubert K., and Ansorge S. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology 91 (1997) 354-360
16. Richter B., Bandeira-Echtler E., Bergerhoff K., and Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 4 (2008) 753-768
17. Richter B., Bandeira-Echtler E., Bergerhoff K., and Lerch C.L. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews (2008) CD006739
18. Steinbrecher A., Reinhold D., Quigley L., Gado A., Tresser N., Izikson L., Born I., Faust J., Neubert K., et al. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. Journal of Immunology 166 (2001) 2041-2048